---
title: "Obefazimod (ABX464) in Ulcerative colitis: Aminosalicylates"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Aminosalicylates. Topics: Recommendations against 5-ASA added to advanced therapy: ACG 2025 guideline; Recommendations for 5-ASA in mildly to moderately active disease: ACG 2025 guideline; Recommendation to stop 5-ASA after escalation: AGA 2024 living guideline; Recommendations for 5-ASA induction, maintenance, and discontinuation: ECCO 2026 guideline; 4 further topics. 8 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/aminosalicylates"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Aminosalicylates

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Aminosalicylates

<a id="topic-2.2.2.1.1-1"></a>

### Recommendations against 5-ASA added to advanced therapy: ACG 2025 guideline

> “32. In patients with moderately to severely active UC who have failed 5-ASA therapy and in whom advanced therapies with biologics or JAK inhibitors are used for induction of remission, we suggest against using 5-ASA for added clinical efficacy (Conditional recommendation, very low quality of evidence).”
> “34. In patients with prior moderately to severely active UC who have achieved remission but previously failed 5-ASA therapy and are now on anti-TNF therapy, we suggest against using concomitant 5-ASA for efficacy of maintenance of remission (162) (Conditional recommendation, low quality of evidence).”
> “In addition, analyses of whether there is efficacy benefit or increased risk of relapse with continuing 5-ASA or withdrawing it, respectively, have demonstrated no benefit to continuation and no harm to stopping 5-ASA in these settings, and a subsequent cost-effectiveness evaluation suggested that it is more cost effective to stop 5-ASA after advanced treatment is needed (217–219).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.1-2"></a>

### Recommendations for 5-ASA in mildly to moderately active disease: ACG 2025 guideline

> “12. In patients with mildly to moderately active extensive colitis, oral 5-ASA at a dose of at least 2.0 g daily is recommended to induce remission (Strong recommendation, moderate quality of evidence).”
> “14. In patients with mildly to moderately active UC who fail to reach remission with appropriately dosed 5-ASA (at least 2–4.8 g daily oral mesalamine and/or at least 1 g daily rectal mesalamine), we suggest against changing to an alternate 5-ASA formulation to induce remission. Alternative therapeutic classes should be considered (Conditional recommendation, low quality of evidence).”
> “19. In patients with mildly active left-sided or extensive UC, we recommend oral 5-ASA therapy (at least 1.5 g/d) for maintenance of remission (Strong recommendation, moderate quality of evidence).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.1-3"></a>

### Recommendation to stop 5-ASA after escalation: AGA 2024 living guideline

> “13. In adult outpatients with moderate-to-severe UC, who have failed 5-ASAs, and have escalated to therapy with immunomodulators or advanced therapies, the AGA suggests stopping 5-ASAs. [Conditional recommendation, low certainty of evidence]”
> “Large observational studies have suggested no difference in the risk of adverse clinical outcomes between patients who continue vs. stop 5-ASA after starting advanced therapies or immunomodulators99–101.”
> “The guideline panel also acknowledged that one proposed benefit of long-term 5-ASA use is potential chemoprevention effect against colorectal cancer, but this remains unproven.”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

<a id="topic-2.2.2.1.1-4"></a>

### Recommendations for 5-ASA induction, maintenance, and discontinuation: ECCO 2026 guideline

> “We recommend oral 5-aminosalicylates to induce remission in patients with mild-to-moderate ulcerative colitis [strong recommendation, low certainty of evidence] [Agreement: 100%]”
> “We recommend an oral dose of ≥2 g/day of 5-aminosalicylates to maintain remission in patients with mild-to-moderate ulcerative colitis [strong recommendation, very low certainty of evidence] [Agreement: 100%]”
> “We suggest discontinuing oral 5-aminosalicylates in patients with active ulcerative colitis initiating advanced therapy [weak recommendation, low certainty of evidence] [Agreement: 82%]”
> “We suggest discontinuing oral 5-aminosalicylates in patients with ulcerative colitis who achieved remission with advanced therapy or immunomodulators [weak recommendation, low certainty of evidence] [Agreement: 100%]”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.1-5"></a>

### Efficacy of oral 5-ASA versus placebo: ECCO 2026 meta-analysis

> “We performed a meta-analysis of 11 eligible RCTs including a total of 2156 patients evaluated over 4–12 weeks; 5-ASA showed significantly higher efficacy in achieving clinical remission [RR: 1.56; 95% CI: 1.24–1.97] compared with placebo.”
> “5-ASA therapy has demonstrated efficacy for induction of moderately active but not for severely active UC.”
> “According to post-hoc analyses of RCT data, the continuation of 5-ASA in patients with UC initiating advanced therapies appears to provide no additional therapeutic benefit”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.1-6"></a>

### Indication of delayed-release mesalamine tablets

> “induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis.”
> “For induction of remission: 2.4 g to 4.8 g (two to four 1.2-g tablets) once daily.”

Source: [Lialda prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022000s030lbl.pdf)

<a id="topic-2.2.2.1.1-7"></a>

### Remission at Week 8 in two placebo-controlled induction trials of delayed-release mesalamine tablets

| Dose | Study 1 (n=262) n/N (%) | Study 2 (n=255) n/N (%) |
| --- | --- | --- |
| Mesalamine 2.4 g/day | “30/88 (34)” | “34/84 (41)” |
| Mesalamine 4.8 g/day | “26/89 (29)” | “35/85 (41)” |
| Placebo | “11/85 (13)” | “19/86 (22)” |

Source: [Lialda prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022000s030lbl.pdf)

<a id="topic-2.2.2.1.1-8"></a>

### Warnings and precautions for mesalamine

> “Renal Impairment: Assess renal function at the beginning of treatment and periodically during treatment.”
> “Discontinue LIALDA if renal function deteriorates while on therapy.”
> “Mesalamine-Induced Acute Intolerance Syndrome: Symptoms may be difficult to distinguish from an ulcerative colitis exacerbation.”
> “Hypersensitivity Reactions, including myocarditis and pericarditis: Evaluate patients immediately and discontinue LIALDA if a hypersensitivity reaction is suspected.”

Source: [Lialda prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022000s030lbl.pdf)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
